India, July 30 -- This Pharma Stock, engaged in providing contract research, development, and manufacturing services for pharmaceutical, biotechnology, nutrition, animal health, and consumer healthcare companies across global markets, crashed 9.22 percent after the company reported weak June quarterly results, despite Macquarie maintaining an 'Outperform' rating on the stock.

Despite the disappointing performance, Macquarie maintained its 'Outperform' rating, citing confidence in the company's long-term CDMO growth strategy, stable EBITDA margin guidance, and expected improvement in business performance during the second half of FY27.

With a market capitalization of Rs. 16,142.73 crores, the share of Syngene International Limited has r...